Michael Kauffman, Chief Executive Officer at Karyopharm Therapeutics Inc. (KPTI), sold 1,477 shares at $15.00 ($22K) on 2020-08-17, disclosed to the SEC on 2020-08-18.
Scheduled sale ($22k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KPTI | SELL | 2022-03-02 | $128K | — | Filing → |
| KPTI | SELL | 2022-02-22 | $440K | — | Filing → |
| KPTI | SELL | 2022-02-09 | $266K | — | Filing → |